Compare Bristol-Myers Squibb Co (BMY) vs Corning Incorporated (GLW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Corning Incorporated — how do they compare? Bristol-Myers Squibb Co trades at $63.58 (market cap $129.94B), while Corning Incorporated trades at $167.35 (market cap $137.12B). The key difference: Bristol-Myers Squibb Co and Corning Incorporated are close in size by market cap, and Bristol-Myers Squibb Co pays the higher dividend (3.96%). Which is the better fit depends on your goals.
| BMY | GLW | |
|---|---|---|
Market Cap | $129.94B | $137.12B |
Sector | Health | Technology |
52-Week High | $65.89 | $255.79 |
52-Week Low | $42.60 | $64.52 |
Enterprise Value | $163.92B | $144.00B |
Dividend Yield | 3.96% | 0.7% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $63.83, down 1.56% today, with strong technical bullish signals and consistent earnings beats. The stock shows robust fundamentals with a 14.01 P/E ratio, 18.87% net margin, and recent $2.3 billion manufacturing investment. Analyst consensus leans neutral with a $68.56 price target, while technical indicators suggest bullish momentum with key support at $63.
BMY presents a balanced opportunity with strong profitability and growth pipeline offset by patent expiration risks. The stock's current valuation appears reasonable with upside potential to analyst targets, though investors should monitor debt levels and competitive pressures in the pharmaceutical sector.
GLW trades at $166.95, up 5.84% in the last session, with a bearish technical signal but strong recent earnings beats. The company reported Q2 2026 EPS of $0.78, beating expectations, driven by 17% YoY core sales growth from optical and AI data center demand. Valuation ratios are elevated, with a P/E of 73.36 and P/S of 8.23, while profitability improved with a net income margin of 11.2% in 2025.
The outlook is supported by AI infrastructure growth and analyst optimism, with a consensus price target of $193.33 implying 16% upside. Risks include premium valuation sensitivity and execution challenges in scaling solar and optical segments. Cash flow is projected to turn positive in 2026, but debt-to-asset ratio remains elevated at 27.67%.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Corning Incorporated
Corning Inc is a leader in materials science, specializing in the production of glass, ceramics and optical fiber. The firm supplies its products for a wide range of applications, from flat-panel displays in televisions to gasoline particulate filters in automobiles to optical fiber for broadband access, with a leading share in many of its end markets.
Read more on GLW →
